Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Eric Gottenberg

Showing results (111-120 of 311) with videos related to

Pageof 32
Sort By:
Arthritis and Rheumatism|July 1, 2009
The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndromeCorinne Miceli-Richard, Nicolas Gestermann, Marc Ittah, et al.
Arthritis and Rheumatism|May 4, 2011
Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritisAlain Meyer, Emmanuel Chatelus, Daniel Wendling, et al.
Clinical and Experimental Rheumatology|February 21, 2012
Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registryArsene Mekinian, Philippe Ravaud, Claire Larroche, et al.
Bio-Medical Materials and Engineering|December 25, 2014
Nanostructured thick 3D nanofibrous scaffold can induce boneSandy Eap, David Morand, François Clauss, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Association of Anti-Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid ArthritisRaphaèle Seror, Sandrine Le Gall-David, Martine Bonnaure-Mallet, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Plos One|November 1, 2014
MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblastsGhada Alsaleh, Antoine François, Lucas Philippe, et al.
Seminars in Arthritis and Rheumatism|December 28, 2020
Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatmentsMarc Scherlinger, Johanna Lutz, Gael Galli, et al.
RMD Open|August 29, 2024
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's diseaseRenaud Felten, Anne-Perrine Foray, Pascal Schneider, et al.
The Lancet. Rheumatology|November 15, 2021
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximabRenaud Felten, Floriane Gallais, Cédric Schleiss, et al.
Pageof 32

Showing results (111-120 of 311) with videos related to

Sort By:
Pageof 32
Arthritis and Rheumatism|July 1, 2009
The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndromeCorinne Miceli-Richard, Nicolas Gestermann, Marc Ittah, et al.
Arthritis and Rheumatism|May 4, 2011
Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritisAlain Meyer, Emmanuel Chatelus, Daniel Wendling, et al.
Clinical and Experimental Rheumatology|February 21, 2012
Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registryArsene Mekinian, Philippe Ravaud, Claire Larroche, et al.
Bio-Medical Materials and Engineering|December 25, 2014
Nanostructured thick 3D nanofibrous scaffold can induce boneSandy Eap, David Morand, François Clauss, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Association of Anti-Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid ArthritisRaphaèle Seror, Sandrine Le Gall-David, Martine Bonnaure-Mallet, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Plos One|November 1, 2014
MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblastsGhada Alsaleh, Antoine François, Lucas Philippe, et al.
Seminars in Arthritis and Rheumatism|December 28, 2020
Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatmentsMarc Scherlinger, Johanna Lutz, Gael Galli, et al.
RMD Open|August 29, 2024
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's diseaseRenaud Felten, Anne-Perrine Foray, Pascal Schneider, et al.
The Lancet. Rheumatology|November 15, 2021
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximabRenaud Felten, Floriane Gallais, Cédric Schleiss, et al.
Pageof 32